



Flash BioSolutions launches GMP production of revolutionary mRNA technology for next-generation vaccines and therapies

Toulouse, Occitanie, France, 26 September 2024 – Flash BioSolutions is proud to announce the commencement of industrial-scale GMP production of its revolutionary mRNA technology, FlashRNA[®], at its state-of-the-art facility in Toulouse, starting October 2024. Commissioned in 2023, this facility represents a significant step forward in the manufacturing of RNA-based therapeutics.

FlashRNA[®] is a cutting-edge mRNA platform providing the highest possible level of safety as a ready-to-inject drug product, offering transformative potential not only in RNA vaccines, but also in a wide range of cell and gene therapy applications. This safe technology promises to be a game-changer, enabling the next generation of medical treatments, particularly in the realm of infectious diseases.

The mRNA vaccine market is experiencing explosive growth, with projections indicating a compound annual growth rate of over 30% through 2030^[1]. This surge is driven by the success of COVID-19 vaccines and the expanding pipeline of mRNA vaccines for various infectious diseases, including influenza, Zika, and respiratory syncytial virus (RSV)^[2].

FlashRNA[®] is poised to play a key role in this rapidly evolving landscape. Its unique technology, inspired by nature's own mechanisms for RNA transfer, offers unparalleled efficiency in mRNA delivery. This breakthrough could significantly enhance the development of vaccines against a wide array of pathogens, potentially revolutionizing our approach to infectious disease prevention and treatment^[3].

*"Our commitment to innovation and excellence in RNA technology is reflected in the launch of GMP production for FlashRNA[®]," said **Christine Duthoit, CSO of Flash BioSolutions**. "This milestone is a testament to the hard work and dedication of our development and transfer teams, as well as our operations and quality teams, whose joint efforts have made this achievement possible."*

***Anne Deflisque, Business Director**, added, "The start of industrial-scale GMP production is a critical step in bringing our groundbreaking solutions to market. With FlashRNA[®], we're not just participating in the mRNA revolution – we're helping to lead it. Our technology's efficiency and versatility position us uniquely to address the growing demand for mRNA-based solutions in infectious disease control and beyond."*

***Jérôme Bédier, CEO**, concluded, "Flash BioSolutions is at the forefront of mRNA technology, and with FlashRNA[®], we are set to make a significant impact on the future of medicine. Our technology's ability to vehicle RNA with unprecedented efficiency could accelerate the development of vaccines for challenging infectious diseases and improve global health outcomes. We congratulate our entire team for their exceptional work in reaching this pivotal moment."*

[1] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619190/>

[2] <https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.00594/full>

[3] <https://www.pennmedicine.org/mrna>

About Flash BioSolutions:

Flash BioSolutions® is a preeminent CDMO specializing in the industrial-scale production of DNA and RNA vectors for clientele within the domains of gene and cell therapy, and vaccine development. Bolstered by a robust manufacturing platform and validated processes honed over two decades, Flash BioSolutions® excels in delivering vectors of unmatched purity and concentration across research, pre-clinical, clinical, and commercial phases.

Contact :

Head of communication
Soraya Sandokchi
+33 582 955 546
soraya.sandokchi@flashbiosolutions.com